IDEA EV06

Phase:
I
Status:
Completed
Strategies:
DNA, Protein
Candidates:
DNA-HIV-PT123, AIDSVAX B/E
Countries:
Uganda
Volunteers:
72
Partners:
IAVI; EuroVacc Foundation
 

A phase I double blind placebo-controlled clinical trial to evaluate the safety and immunogenicity of the combination of DNA-HIV-PT123 and AIDSVAX ® B/E in HIV-1-uninfected adult participants with or without underlying Schistosoma mansoni (S. mansoni) infection.

ClinicalTrials.gov Identifier: NCT02376582